Neuroinflammation in Patients With OCD

• Status: Recruiting
• Trial end date: 2024-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this study is to examine whether measurements of inflammation from brain scanning and blood tests can predict how much benefit patients with obsessive-compulsive disorder (OCD) will have from treatment with an anti-inflammatory medication, celecoxib, when adding to ongoing medication-based treatment for OCD.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: New York State Psychiatric Institute
• Collaborator: International OCD Foundation
• Treatments: Celecoxib

Criteria

Inclusion Criteria:

• 18 to 55 years old

• Principal diagnosis of Obsessive-Compulsive Disorder (OCD)

• Ongoing OCD symptoms despite current treatment with psychiatric medication

• Capacity to provide informed consent

Exclusion Criteria:

• Psychiatric comorbidities that would increase risk of participation or impact research measures (e.g., suicidality)

• Medical or neurological conditions that would increase risk of participation or impact research measures

• Contraindications to an MRI or PET scan (e.g., metal implants)

• Current use of medications that may interact with study drug or impact research measures (e.g., antipsychotics, corticosteroids, immunosuppressant medications, or daily non-steroidal anti-inflammatory medications)

• Starting a new evidence-based therapy for OCD (e.g., exposure with response prevention) 4 weeks prior to study enrollment